NASOPHARYNGEAL CANCINOMA (NPC)

This study tests whether adding the immunotherapy drug Toripalimab to different platinum-based chemotherapy regimens, followed by standard chemoradiation, can improve outcomes for people with locally advanced nasopharyngeal cancer. About 243 participants will be randomly assigned…

This study tests if proton radiation therapy combined with carbon ion therapy works as well as standard photon radiation with carbon ion therapy for people with newly diagnosed nasopharyngeal cancer. About 470 participants will be randomly assigned to one of the two treatment gro…

This study tests whether combining an EGFR antibody, a PD-1 inhibitor, and chemotherapy can help people with nasopharyngeal carcinoma that has come back or spread. About 148 adults aged 18-75 who have not had prior treatment for their advanced cancer will receive this triple ther…

This study tests a new drug (HMBD-001) combined with standard treatments (cetuximab, with or without docetaxel) in people with advanced squamous cell cancers that have spread. The goal is to see if the combination is safe and can help control the cancer or slow its growth. About …

This study looks at whether using only targeted radiation (IMRT) can effectively control stage IB nasopharyngeal cancer in patients without high-risk features. Researchers will track how long participants stay cancer-free after treatment. The goal is to see if radiation alone can…

This study tests a drug called becotatug vedotin in people with advanced nasopharyngeal cancer whose tumors didn't shrink enough after initial chemotherapy and immunotherapy. About 59 participants will receive the drug during and after radiation therapy. The goal is to see if it …

This phase 3 trial tests whether adding immunotherapy to standard treatment can improve outcomes for people with advanced nasopharyngeal cancer. About 802 participants will be split into low-risk and high-risk groups to see if some can safely skip harsh chemotherapy or benefit fr…

This study compares a reduced dose of radiation to the standard dose for low-risk areas in people with nasopharyngeal cancer. The goal is to see if the lower dose can control the cancer just as well while causing fewer side effects and improving quality of life. About 700 adults …

This study tests whether adding low-dose radiation to standard chemoimmunotherapy can better control liver tumors in people with nasopharyngeal cancer that has spread to the liver. About 26 adults aged 18-70 with newly diagnosed or recurrent liver metastases will receive the comb…

This study tests whether adding low-dose radiation to a standard chemotherapy and immunotherapy combination can help control advanced nasopharyngeal cancer that has returned or spread. About 55 adults aged 18-65 with this specific cancer type will receive the treatment. The goal …

This study tests whether adding Houyanqing Oral Liquid to standard care can prevent severe mouth sores caused by radiation therapy in people with nasopharyngeal cancer. About 386 participants will be randomly assigned to receive either the herbal liquid plus usual treatment or us…

This study looks at 500 people with nasopharyngeal cancer who are getting either proton or photon radiation therapy. Researchers want to find biological markers that can predict how well the treatment works and what side effects might occur. The goal is to better understand the d…

This study aims to improve how doctors classify nasopharyngeal cancer (NPC) to better predict outcomes and guide treatment. Researchers will collect detailed data from 5000 patients worldwide, including those from regions where NPC is common and those where it is rare. Participan…